Evidence map›Paper›PMID 41165345›Full record

ArticleCirculation research2025

YAP-Induced Glycolysis Drives Fibroinflammation and Disrupts Fibroblast Fidelity.

Chang-Ru Tsai, Lin Liu, Yi Zhao, Jong H Kim, Paulo Czarnewski, Rich Gang Li, Fansen Meng, Mingjie Zheng, Jeffrey Steimle, Xiaolei Zhao and 6 more

Abstract read
In one paragraph

Article in Circulation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Lactylation in cardiac repair: Nexus and therapeutic opportunity.Journal of molecular and cellular cardiology plus · 2026
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chang-Ru TsaiDepartment of Integrative Physiology (C.-R.T., J.S., F.G., M.A.H.S., J.F.M.), Baylor College of Medicine, Houston, TX.ORCID 0000-0001-5672-1235
Lin LiuThe Texas Heart Institute at Baylor College of Medicine, Houston, TX (L.L., Y.Z., J.H.K., R.G.L., F.M., F.G., X.L., J.F.M.).ORCID 0000-0002-0343-6286
Yi ZhaoThe Texas Heart Institute at Baylor College of Medicine, Houston, TX (L.L., Y.Z., J.H.K., R.G.L., F.M., F.G., X.L., J.F.M.).ORCID 0000-0003-0989-8825
Jong H KimThe Texas Heart Institute at Baylor College of Medicine, Houston, TX (L.L., Y.Z., J.H.K., R.G.L., F.M., F.G., X.L., J.F.M.).ORCID 0000-0002-4491-212X
Paulo CzarnewskiScience for Life Laboratory, Stockholm University, Sweden (P.C.).ORCID 0000-0001-8150-4021
Rich Gang LiThe Texas Heart Institute at Baylor College of Medicine, Houston, TX (L.L., Y.Z., J.H.K., R.G.L., F.M., F.G., X.L., J.F.M.).ORCID 0000-0001-9661-8304
Fansen MengThe Texas Heart Institute at Baylor College of Medicine, Houston, TX (L.L., Y.Z., J.H.K., R.G.L., F.M., F.G., X.L., J.F.M.).
Mingjie ZhengDepartment of Pediatrics, McGovern Medical School, University of Texas Health Science Center at Houston, TX (M.Z., X.Z., J.W.).
Jeffrey SteimleDepartment of Integrative Physiology (C.-R.T., J.S., F.G., M.A.H.S., J.F.M.), Baylor College of Medicine, Houston, TX.ORCID 0000-0002-1369-9661
Xiaolei ZhaoDepartment of Pediatrics, McGovern Medical School, University of Texas Health Science Center at Houston, TX (M.Z., X.Z., J.W.).ORCID 0000-0002-4697-3874
Francisco GrisantiDepartment of Integrative Physiology (C.-R.T., J.S., F.G., M.A.H.S., J.F.M.), Baylor College of Medicine, Houston, TX.
Zheng SunDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine (Z.S.), Baylor College of Medicine, Houston, TX.ORCID 0000-0002-6858-0633
Jun WangDepartment of Pediatrics, McGovern Medical School, University of Texas Health Science Center at Houston, TX (M.Z., X.Z., J.W.).ORCID 0000-0001-6874-9331
Md Abul Hassan SameeDepartment of Integrative Physiology (C.-R.T., J.S., F.G., M.A.H.S., J.F.M.), Baylor College of Medicine, Houston, TX.ORCID 0000-0002-7472-1156
Xiao LiThe Texas Heart Institute at Baylor College of Medicine, Houston, TX (L.L., Y.Z., J.H.K., R.G.L., F.M., F.G., X.L., J.F.M.).ORCID 0000-0001-8527-4438
James F MartinDepartment of Integrative Physiology (C.-R.T., J.S., F.G., M.A.H.S., J.F.M.), Baylor College of Medicine, Houston, TX.ORCID 0000-0002-7842-9857

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
UM1HG006348: Cas9 Genome Integrity Supplemental ProposalUM1HG006348 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI Jason D. Heaney, Chih-Wei Logan Hsu · 2016 to 2026
$47.5M
Pitx2 in atrial fibrillationR01HL118761 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI MARTIN, JAMES F · 2014 to 2025
$6.1M
Noradrenergic mechanisms in breathing and respiratory pathophysiologiesR01HL130249 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI RAY, RUSSELL S · 2016 to 2024
$5.3M
METABOLIC IMPACTS OF TYPE II INTERFERON SIGNALS IN OBESITYR01DK114356 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI HARTIG, SEAN · 2017 to 2025
$4.6M
Genetic dissection of Cardiac Conduction System homeostasis and RepairR01HL142704 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Jun Wang · 2020 to 2026
$3.0M
Research Training Program in Cardiovascular SurgeryT32HL139430 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Todd K Rosengart · 2018 to 2026
$2.9M
Cytoskeletal Control of Yap in Heart RegenerationR01HL169511 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI James F Martin · 2023 to 2026
$2.7M
Cardiac Circadian Clock and Dilated CardiomyopathyR01HL153320 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI SUN, ZHENG · 2020 to 2023
$1.9M
Reawakening cardiomyocyte proliferation from structural mediated quiescenceR01HL171574 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI James F Martin, Sean M Wu · 2024 to 2026
$1.9M
Hippo-YAP signaling in cardiac regenerative repairR01HL173242 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI James F Martin · 2025 to 2026
$1.4M
Senescent Cell States in Single Ventricle Disease with Heart FailureR01HL177644 · NHLBI · TEXAS HEART INSTITUTE · PI James F Martin · 2025 to 2026
$1.3M
NCI NIH HHS P30 CA125123NHGRI NIH HHS UM1 HG006348NHLBI NIH HHS K99 HL169742NHLBI NIH HHS R00 HL169742NHLBI NIH HHS R01 HL118761NHLBI NIH HHS R01 HL130249NHLBI NIH HHS R01 HL142704NHLBI NIH HHS R01 HL153320NHLBI NIH HHS R01 HL169511NHLBI NIH HHS R01 HL171574NHLBI NIH HHS R01 HL173242NHLBI NIH HHS R01 HL177644NHLBI NIH HHS R01 HL179012NHLBI NIH HHS R56 HL142704NHLBI NIH HHS T32 HL139430NIDDK NIH HHS R01 DK114356
6 · The paper itself

Abstract

backgroundSeparation of the pulmonic and systemic circulation is essential for terrestrial life, and mammals have evolved distinct cardiac chambers with specialized structures and functions. Transcriptomics profiling revealed cellular heterogeneity between heart chambers. However, the mechanisms underlying chamber-specific transcriptomic and metabolic differences-and their functional significance-remain poorly understood. The Hippo/YAP (yes-associated protein) pathway is a conserved signaling network that regulates diverse cellular processes. The Hippo kinases inhibit YAP in cardiac fibroblasts (CF) to restrict fibrosis and inflammation. Nonetheless, how YAP regulates the metabolic microenvironment during homeostasis and fibroinflammation remains unclear.

methodsWe investigated YAP and glycolysis activity in the 4 cardiac chambers by scoring the expression of YAP target genes and glycolysis genes in human single-nucleus RNA sequencing data. To compare glucose uptake between the left and right atria, we measured isotope-labeled glucose uptake in isolated mouse atria. To study the role of YAP in CFs, we inactivated the Hippo kinases,

resultsMetabolic and sequencing approaches revealed that Hippo-deficient CFs activated glycolysis to promote fibroinflammation. Inhibition of glycolysis or lactate production suppressed Hippo-deficient CF-induced fibrosis. Elevated YAP activity disrupted fibroblast lineage fidelity by inducing an osteochondroprogenitor cell state. Blocking macrophage expansion pharmacologically reduced Hippo-deficient CF proliferation and fibrosis. Sequencing and functional studies showed that macrophages secreted IGF1 (insulin-like growth factor 1) to activate IGF1 signaling in Hippo-deficient CFs to increase cell proliferation and fibrosis.

conclusionsWe discovered that right atrial CFs are more glycolytic and have higher YAP activity than CFs in other heart chambers. YAP activation in CFs induces glycolysis to drive fibrosis. YAP disrupts fibroblast lineage fidelity, driving them to a SOX9 (SRY-box transcription factor 9)-expressing osteochondroprogenitor cell state. Mechanistically, YAP activates the secretion of CSF1 (colony-stimulating factor 1) to promote macrophage expansion. Blocking macrophage expansion reduces Hippo-deficient CF proliferation, osteochondroprogenitor differentiation, and fibrosis, revealing that macrophages signal reciprocally to regulate CF cell states. Genomic and functional studies revealed that the upregulated IGF1 receptor in Hippo-deficient CFs enables them to receive macrophage-secreted IGF1, thereby further enhancing CF proliferation and fibrosis.

Indexed as

Adaptor Proteins, Signal TransducingCell Cycle ProteinsFibroblastsGlycolysisAnimalsCells, CulturedFibrosisHeart AtriaHippo Signaling PathwayHumansInflammationMaleMiceMice, Inbred C57BLMice, KnockoutProtein Serine-Threonine KinasesAdaptor Proteins, Signal TransducingCell Cycle ProteinsLats1 protein, mouseProtein Serine-Threonine KinasesYAP1 protein, humanYap1 protein, mouseYAP-Signaling Proteinsfibroblastfibrosisglycolysishippo signaling pathwayinflammation

Identifiers

PMID41165345
PMCPMC12965804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.